Market cap
$377 Mln
Revenue (TTM)
$58 Mln
P/E Ratio
--
P/B Ratio
15.3
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 14.30 | -60.97 | -34.73 | -3.10 | -- |
| EBIT | 60.93 | -127.77 | 41.93 | 17.26 | 10.40 |
| Net Profit | 46.48 | -162.79 | 45.89 | 16.10 | 9.11 |
| EPS | 46.48 | -173.66 | 53.09 | 18.49 | 11.09 |
| Book Value | -- | -- | -56.45 | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-23 | Dec-22 |
| EBIT-Margin
| -255.64 | -1,402.06 | -65.31 | -47.91 | -263.99 |
| Net Margin
| -457.12 | -634.53 | -76.93 | -- | -354.54 |
| Return on equity
| -1.94 | 12.83 | -149.29 | -92.13 | 57.23 |
| Return on Capital
| 26.12 | 30.17 | -- | -39.15 | 84.59 |
| Return on Assets
| -53.08 | -47.02 | -28.16 | -31.00 | -66.76 |
| Debt to Equity (x)
| -- | -- | 1.34 | 1.62 | 1.22 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
--
|
-39.15
|
84.59
|
32.93
|
27.33
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-149.29
Lower than Peers by 108.89
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
-149.29
|
-92.13
|
57.23
|
29.07
|
25.68
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-28.16
Higher than Peers by 2.82
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
-28.16
|
-31.00
|
-66.76
|
-61.47
|
-38.67
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
-65.31
Higher than Peers by 18.31
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
-65.31
|
-47.91
|
-263.99
|
-455.04
|
-213.42
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
-76.93
Higher than Peers by 15.74
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
-76.93
|
-58.13
|
-354.54
|
-559.69
|
-226.00
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
-34.73
Lower than Peers by 88.69
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
-34.73
|
0.61
|
0.63
|
-0.30
|
20.16
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
41.93
Higher than Peers by 42.73
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
41.93
|
70.81
|
5.45
|
-48.20
|
25.10
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
45.89
Higher than Peers by 53.19
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
45.89
|
67.49
|
0.53
|
-49.47
|
18.70
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
53.09
Higher than Peers by 38.44
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
53.09
|
0.72
|
0.05
|
-0.35
|
0.21
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
-49.87
Lower than Peers by 39.69
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
-49.87
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
1.34
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
1.34
|
1.62
|
1.22
|
-0.14
|
-0.08
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.46
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
0.46
|
0.04
|
0.02
|
0.00
|
-0.04
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
2.48
Lower than Peers by 3.33
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
2.48
|
3.87
|
5.04
|
8.82
|
9.23
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
2.12
Lower than Peers by 3.58
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
2.12
|
3.45
|
4.59
|
8.69
|
9.23
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-3.80
Lower than Peers by 1.72
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
-3.80
|
-3.94
|
-12.98
|
-30.69
|
-54.36
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
22.87
Higher than Peers by 3.73
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
22.87
|
15.38
|
21.63
|
18.07
|
0.52
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
0.37
Higher than Peers by 0.30
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
0.37
|
0.53
|
0.23
|
0.13
|
0.18
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
--
|
52.64
|
59.74
|
34.38
|
1.91
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
--
|
726.46
|
957.47
|
314.43
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
--
|
289.94
|
503.24
|
586.01
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
--
|
489.16
|
513.97
|
-237.21
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
--
|
-3.31
|
-1.62
|
-2.89
|
-6.89
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
15.34
Higher than Peers by 10.16
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
15.34
|
4.48
|
3.48
|
-0.73
|
-1.57
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-6.16
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
-6.16
|
-3.42
|
-1.32
|
-2.04
|
-5.34
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
377
Higher than Peers by 231
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
G1 Therapeutics (GTHX)
|
377
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|